Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results deaths Eviral clearance Ehospitalization for COVID19 or death E

COVID-19 prophylaxis meta-analysis

Abella, 2020
 
NCT04329923
hydroxychloroquineplaceboCOVID-19 prophylaxisNA
65/65 safety concern
Barnabas RV, 2020
 
NCT04328961
RCThydroxychloroquineplaceboCOVID-19 prophylaxislow
407/422 safety concern
BCN PEP-CoV-2-Study 1 (Mitja NEJM), 2020
 
NCT04304053
RCThydroxychloroquinestandard of careCOVID-19 prophylaxissome concern
1116/1198 safety concern -29%
COVID PREP HCQ 1x week (Rajasingham), 2020
 
NCT04328467
RCThydroxychloroquineplaceboCOVID-19 prophylaxislow
494/494 suggested
COVID PREP HCQ 2x week (Rajasingham), 2020
 
NCT04328467
RCThydroxychloroquineplaceboCOVID-19 prophylaxislow
495/494 safety concern
COVID-PEP-Post exposure (Boulware), 2020
 
NCT04308668
RCThydroxychloroquineplaceboCOVID-19 prophylaxislow
414/407 safety concern -2%
Grau-Pujol, 2020
 
NCT04331834
RCThydroxychloroquineplaceboCOVID-19 prophylaxissome concern
142/127 inconclusive
PATCH-cohort 3 PreP (Abella), 2020
 
NCT04329923
RCThydroxychloroquineplaceboCOVID-19 prophylaxissome concern
66/66 inconclusive 0%
Rentsch, 2020 OBShydroxychloroquineCOVID-19 prophylaxisNA
-/- ongoing

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).